KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.151 $0.151 Wednesday, 19th Apr 2023 CLVS stock ended at $0.151. During the day the stock fluctuated 0% from a day low at $0.151 to a day high of $0.151.
90 days $0.120 $0.168
52 weeks $0.0471 $3.25

Historical Clovis Oncology prices

Date Open High Low Close Volume
Jan 20, 2016 $21.29 $22.88 $19.80 $22.28 2 061 900
Jan 19, 2016 $22.90 $23.42 $21.17 $21.81 1 217 000
Jan 15, 2016 $22.79 $23.39 $21.78 $22.52 1 400 800
Jan 14, 2016 $24.52 $25.20 $21.78 $23.82 2 042 000
Jan 13, 2016 $27.60 $27.78 $24.00 $24.18 1 521 700
Jan 12, 2016 $26.83 $28.13 $26.13 $27.45 1 159 500
Jan 11, 2016 $29.37 $29.76 $25.33 $26.14 1 818 000
Jan 08, 2016 $30.15 $31.46 $29.03 $29.17 749 400
Jan 07, 2016 $29.57 $30.35 $29.18 $29.83 1 184 000
Jan 06, 2016 $31.13 $31.77 $30.22 $30.80 996 800
Jan 05, 2016 $33.50 $34.00 $31.33 $31.70 1 192 000
Click to get the best stock tips daily for free!

About Clovis Oncology

Clovis Oncology Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the... CLVS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT